Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis.
Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis.
复制标题
DOI:
10.1186/s12916-021-01948-z
复制
发表时间:
2021-03-09
期刊:
影响因子:
9.3
通讯作者:
Arinaminpathy N
中科院分区:
文献类型:
--
作者:
Ricks S;Kendall EA;Dowdy DW;Sacks JA;Schumacher SG;Arinaminpathy N
Testing plays a critical role in treatment and prevention responses to the COVID-19 pandemic. Compared to nucleic acid tests (NATs), antigen-detection rapid diagnostic tests (Ag-RDTs) can be more accessible, but typically have lower sensitivity and specificity. By quantifying these trade-offs, we aimed to inform decisions about when an Ag-RDT would offer greater public health value than reliance on NAT. Following an expert consultation, we selected two use cases for analysis: rapid identification of people with COVID-19 amongst patients admitted with respiratory symptoms in a ‘hospital’ setting and early identification and isolation of people with mildly symptomatic COVID-19 in a ‘community’ setting. Using decision analysis, we evaluated the health system cost and health impact (deaths averted and infectious days isolated) of an Ag-RDT-led strategy, compared to a strategy based on NAT and clinical judgement. We adopted a broad range of values for ‘contextual’ parameters relevant to a range of settings, including the availability of NAT and the performance of clinical judgement. We performed a multivariate sensitivity analysis to all of these parameters. In a hospital setting, an Ag-RDT-led strategy would avert more deaths than a NAT-based strategy, and at lower cost per death averted, when the sensitivity of clinical judgement is less than 90%, and when NAT results are available in time to inform clinical decision-making for less than 85% of patients. The use of an Ag-RDT is robustly supported in community settings, where it would avert more transmission at lower cost than relying on NAT alone, under a wide range of assumptions. Despite their imperfect sensitivity and specificity, Ag-RDTs have the potential to be simultaneously more impactful, and have a lower cost per death and infectious person-days averted, than current approaches to COVID-19 diagnostic testing. The online version contains supplementary material available at 10.1186/s12916-021-01948-z.
登录
查看更多内容
DOI:
10.15585/mmwr.mm6915e3
发表时间:
2020-04-17
期刊:
MMWR. Morbidity and mortality weekly report
影响因子:
--
作者:
Garg S;Kim L;Whitaker M;O'Halloran A;Cummings C;Holstein R;Prill M;Chai SJ;Kirley PD;Alden NB;Kawasaki B;Yousey-Hindes K;Niccolai L;Anderson EJ;Openo KP;Weigel A;Monroe ML;Ryan P;Henderson J;Kim S;Como-Sabetti K;Lynfield R;Sosin D;Torres S;Muse A;Bennett NM;Billing L;Sutton M;West N;Schaffner W;Talbot HK;Aquino C;George A;Budd A;Brammer L;Langley G;Hall AJ;Fry A
通讯作者:
Fry A
影响因子:
9.3
作者:
Mallett S;Allen AJ;Graziadio S;Taylor SA;Sakai NS;Green K;Suklan J;Hyde C;Shinkins B;Zhelev Z;Peters J;Turner PJ;Roberts NW;di Ruffano LF;Wolff R;Whiting P;Winter A;Bhatnagar G;Nicholson BD;Halligan S
通讯作者:
Halligan S
影响因子:
11.1
作者:
Lechien, Jerome R.;Chiesa-Estomba, Carlos M.;Saussez, Sven
通讯作者:
Saussez, Sven
影响因子:
82.9
作者:
He, Xi;Lau, Eric H. Y.;Leung, Gabriel M.
通讯作者:
Leung, Gabriel M.
影响因子:
3.7
作者:
Arevalo-Rodriguez I;Buitrago-Garcia D;Simancas-Racines D;Zambrano-Achig P;Del Campo R;Ciapponi A;Sued O;Martinez-García L;Rutjes AW;Low N;Bossuyt PM;Perez-Molina JA;Zamora J
通讯作者:
Zamora J